文献速递艾滋病与性传播感染

整合酶链转移抑制剂与人类免疫缺陷病毒感染者新发糖尿病相关

Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus.
PubMed 文献 · Clin Infect Dis · 2022-01-01

基于IBM MarketScan数据库纳入2007年7月1日至2018年6月30日新启动抗逆转录病毒治疗的42382例HIV感染者,其中22762例(54%)使用整合酶链转移抑制剂方案。使用INSTI者发生新发糖尿病/高血糖的风险较非INSTI方案者高31%(HR 1.31;95%CI 1.15-1.48)。

要点

  • 使用INSTI方案者新发糖尿病/高血糖风险较非INSTI方案者高31%(HR 1.31;95%CI 1.15-1.48)。
  • 单药分析中依曲韦林风险最高(HR 1.54;95%CI 1.32-1.97;P<.001),拉替拉韦最低(HR 1.19;95%CI 1.03-1.37;P=.02)。
  • 研究纳入42382例新启动ART的HIV感染者,其中54%使用INSTI方案。

核心结论

  • INSTI使用与ART启动后6个月内新发糖尿病/高血糖风险升高相关。

研究设计与样本

  • 使用IBM MarketScan商业保险和Medicaid保险成人数据库识别新启动抗逆转录病毒治疗的HIV感染者。
  • 纳入2007年7月1日至2018年6月30日新启动ART的42382例HIV感染者,其中22762例(54%)使用INSTI方案。
  • 主要结局为ART启动后6个月内新发糖尿病/高血糖的复合终点,通过ICD-9-CM、ICD-10-CM诊断与操作代码及CPT-4代码识别。
  • 采用Cox比例风险模型结合日历时间特异性标准化死亡比权重估计风险。

主要发现

  • 使用INSTI者发生新发糖尿病/高血糖的风险较非INSTI方案者高31%(HR 1.31;95%CI 1.15-1.48)。
  • 单药分析中依曲韦林风险最高(HR 1.54;95%CI 1.32-1.97;P<.001),拉替拉韦风险最低(HR 1.19;95%CI 1.03-1.37;P=.02)。
  • 队列平均年龄38岁,74%为男性,19%为Medicaid保险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are associated with weight gain in people with HIV (PWH). Less is known about the risk of other metabolic outcomes such as diabetes mellitus and hyperglycemia. METHODS: IBM® MarketScan® databases for commercially and Medicaid-insured adults were used to identify PWH newly initiating antiretroviral therapy (ART). The primary outcome was a composite of new-onset diabetes mellitus/hyperglycemia in the 6 months following ART initiation and was identified using International Classification of Disease, Ninth revision, Clinical Modification (ICD-9-CM) and ICD-10-CM diagnosis and procedure codes and Current Procedural Terminology, 4th Edition (CPT-4) codes. To examine the relationship between INSTI use and the composite outcome, we estimated the risk using Cox proportional hazards models with calendar time-specific standardized mortality ratio weights. RESULTS: Of 42 382 PWH who initiated ART between 1 July 2007 and 30 June 2018, 22 762 (54%) were treated with INSTI-based regimens. Mean age was 38 years, 74% were male, and 19% were Medicaid insured. PWH on INSTIs were 31% more likely to develop new-onset diabetes mellitus/hyperglycemia (hazard ratio [HR], 1.31; 95% confidence interval [CI], 1.15-1.48]) compared with those who initiated non-INSTI-based regimens. When examined individually, the highest risk was associated with elvitegravir (HR, 1.54; 95% CI, 1.32-1.97; P < .001) and the lowest risk with raltegravir (HR, 1.19; 95% CI, 1.03-1.37; P = .02). CONCLUSIONS: INSTI use was associated with increased risk of new-onset diabetes mellitus/hyperglycemia in the 6 months following ART initiation.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. O'Halloran JA, Sahrmann J, Parra-Rodriguez L, et al. Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus. Clin Infect Dis. 2022. PMID: 35521785. doi:10.1093/cid/ciac355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。